Loading
Life sciences · Journal article
Scientific Reports · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Real-world comparison of rezvilutamide versus bicalutamide in high-volume metastatic hormone-sensitive prostate cancer (mHSPC) is limited. While the phase III CHART trial established the efficacy of rezvilutamide in a controlled setting, its generalizability to routine clinical practice, particularly in patients excluded from the trial (e.g., those with prior docetaxel exposure), remains uncertain. Multicenter retrospective cohort study of high-volume mHSPC patients receiving ADT plus rezvilutamide or bicalutamide (2021–2024). Propensity-score matching (1:1) yielded 50 patients per group. Calendar year was not included in the primary propensity-score model but was incorporated as a covariate in prespecified sensitivity analyses to address potential treatment-era bias. Primary endpoint: radiographic progression-free survival (rPFS). Rezvilutamide significantly improved median rPFS (25.9 vs. 16.1 months; HR 0.64, 95% CI 0.41–0.98; p = 0.038), time to castration resistance (18.6 vs. 11.4 months; HR 0.61, 95% CI 0.39–0.94; p = 0.026), and time to PSA progression (20.1 vs. 12.9 months; HR 0.57, 95% CI 0.36–0.91; p = 0.018). PSA50 (84% vs. 62%; p = 0.011) and PSA90 (50% vs. 28%; p = 0.022) responses favored rezvilutamide. Overall survival (HR 0.85, 95% CI 0.50–1.43; p = 0.54) and symptomatic skeletal events (HR 0.82, 95% CI 0.44–1.54; p = 0.53) showed numerical benefit without significance. In exploratory analyses of patients with prior docetaxel exposure (24% of each group)—a population excluded from CHART—the rPFS point estimate favored rezvilutamide (HR 0.68, 95% CI 0.30–1.55), though underpowered. Grade ≥ 3 adverse events were comparable (26% vs. 24%). Prespecified CNS-related events, defined using standardized criteria with independent neurologist review, were lower with rezvilutamide (8% vs. 14%). Rezvilutamide plus ADT provides superior disease control to bicalutamide plus ADT in high-volume mHSPC with a favorable safety profile. These real-world findings complement the CHART trial by including populations excluded from the trial, though the modest sample size limits definitive conclusions for subgroups. Longer-term follow-up is needed to confirm survival benefits.